Charles A. Rowland Jr.
Known title: DirectorCIK: 0001383292
Associated companies
Transaction History
| VKTX | ▲ Buy | Grant | 3,150 | $0 | 1/2/2026 | View on chart |
| VKTX | ▼ Sell | Open Market | 60,000 | $2.1M | 10/27/2025 | View on chart |
| VKTX | ▲ Buy | Grant | 16,000 | $72K | 10/27/2025 | View on chart |
| VKTX | ▲ Buy | Grant | 22,000 | $128K | 10/27/2025 | View on chart |
| VKTX | ▲ Buy | Grant | 22,000 | $107K | 10/27/2025 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 40,000 | $43K | 5/16/2023 | View on chart |
| VKTX | ▼ Sell | Open Market | 40,000 | $1.0M | 5/16/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Viking Therapeutics Launches New Oral Obesity Study
Viking Therapeutics announced a new oral maintenance study for its obesity program, a key step in its drug development pipeline. This news comes as the stock has fallen over 30% in the last three months, trading near its 52-week low. While an analyst recently maintained a buy rating with a lowered price target, the broader market view remains mixed given the recent price decline.
Viking Therapeutics Launches New Oral Obesity Study. Viking Therapeutics announced a new oral maintenance study for its obesity program, a key step in its drug development pipeline. This news comes as the stock has fallen over 30% in the last three months, trading near its 52-week low. While an analyst recently maintained a buy rating with a lowered price target, the broader market view remains mixed given the recent price decline.